Skip to main content
SpringerLink
Log in

Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis

  • Gynecologic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Although the standard of care after recurrence of epithelial ovarian cancer (EOC) is chemotherapy, increasing data suggest that combining cytoreductive surgery with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is a promising option for patients with recurrent EOC. Our aim was to determine the prognostic value of the addition of HIPEC to secondary cytoreductive surgery (SCR) in recurrent EOC.

Methods

We analyzed a series of 79 patients with platinum-sensitive recurrent EOC who were treated from May 2000 to January 2014. Fifty patients who underwent SCR were compared to 29 who had SCR in combination with HIPEC.

Results

The SCR group had a higher median age (58.4 years) compared to the SCR + HIPEC group (51.6 years) (p = 0.006). The median hospital stay length was longer for SCR + HIPEC versus SCR patients (11 and 8 days, respectively; p = 0.009). More subjects experienced National Cancer Institute grade III–IV morbidity in the SCR + HIPEC group (34.5 %) compared to the SCR group (10.6 %) (p = 0.015). Conversely, there were no deaths in the SCR + HIPEC group and 2 (4.0 %) deaths the SCR group. The median disease-free survival did not differ between SCR and SCR + HIPEC patients (18.6 and 15.8 months, respectively; p = 0.82); nor did median overall survival (59.3 and 58.3 months, respectively; p = 0.95). The presence of carcinomatosis was the only variable that remained linked to a higher risk of recurrence and death in the multivariate analysis.

Conclusions

Our data suggest that the addition of HIPEC to cytoreduction in patients with recurrent platinum-sensitive EOC does not improve survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. du Bois A, Reuss A, Pujade-Lauraine E, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe dʼInvestigateurs Nationaux Pour les Etudes des Cancers de lʼOvaire (GINECO). Cancer. 2009;115:1234–44.

    Article  PubMed  Google Scholar 

  2. Tewari D, Java JJ, Salani R, et al. Long-term survival advantage and prognostic factors associated withintraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2015;33:1460–6.

    Article  CAS  PubMed  Google Scholar 

  3. Lopez JA, Krikorian JG, Reich SD, et al. Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol. 1985;20:1–9.

    Article  CAS  PubMed  Google Scholar 

  4. Pretorius RG, Hacker NF, Berek JS, et al. Pharmacokinetics of IP cisplatin in refractory ovarian carcinoma. Cancer Treat Rep. 1983;67:1085–92.

    CAS  PubMed  Google Scholar 

  5. Francis P, Rowinsky E, Schneider J, et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol. 1995;13:2961–7.

    CAS  PubMed  Google Scholar 

  6. Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol. 1992;10:1485–91.

    CAS  PubMed  Google Scholar 

  7. Dedrick RL, Myers CE, Bungay PM, DeVita Jr, VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1–11.

    CAS  PubMed  Google Scholar 

  8. Armstrong DK, Bundy B, Wenzel L, et al; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.

    Article  CAS  PubMed  Google Scholar 

  9. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;100:27–32.

    Article  PubMed  Google Scholar 

  10. Al Rawahi T, Lopes AD, Bristow RE, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database Syst Rev. 2013;2:CD008765.

  11. Di Giorgio A, Naticchioni E, Biacchi D, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113:315–25.

    Article  PubMed  Google Scholar 

  12. Pavlov MJ, Kovacevic PA, Ceranic MS, Stamenkovic AB, Ivanovic AM, Kecmanovic DM. Cytoreductive surgery and modified heated intraoperative intraperitoneal chemotherapy (HIPEC) for advanced and recurrent ovarian cancer—12-year single center experience. Eur J Surg Oncol. 2009;35:1186–91.

    Article  CAS  PubMed  Google Scholar 

  13. Helm CW, Richard SD, Pan J, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer. 2010;20:61–9.

    Article  PubMed  Google Scholar 

  14. Roviello F, Pinto E, Corso G, et al. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. J Surg Oncol. 2010;102:663–70.

    Article  PubMed  Google Scholar 

  15. Parson EN, Lentz S, Russell G, Shen P, Levine EA, Stewart JH. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. Am J Surg. 2011;202:481–6.

    Article  PubMed  Google Scholar 

  16. Deraco M, Kusamura S, Virzì S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol. 2011;122:215–20.

    Article  PubMed  Google Scholar 

  17. Bakrin N, Bereder JM, Decullier E, et al; FROGHI (FRench Oncologic and Gynecologic HIPEC) Group. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39:1435–43.

    Article  CAS  PubMed  Google Scholar 

  18. Chiva LM, Gonzalez-Martin A. A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol. 2015;136:130–5.

    Article  PubMed  Google Scholar 

  19. Chua TC, Robertson G, Liauw W, Farrell R, Yan TD, Morris DL. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009;135:1637–45.

    Article  PubMed  Google Scholar 

  20. Bakrin N, Classe JM, Pomel C, Gouy S, Chene G, Glehen O. Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. J Visc Surg. 2014;151:347–53.

    Article  CAS  PubMed  Google Scholar 

  21. Munoz-Casares FC, Rufian S, Rubio MJ, et al. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol. 2009;11:753–9.

    Article  PubMed  Google Scholar 

  22. Fagotti A, Costantini B, Petrillo M, et al. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two-year follow-up. Gynecol Oncol. 2012;127:502–5.

    Article  PubMed  Google Scholar 

  23. Le Brun J, Campion L, Berton-Rigaud D, et al. Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case-control study. Ann Surg Oncol. 2014;21:3621–7.

    Article  PubMed  Google Scholar 

  24. Safra T, Grisaru D, Inbar M, et al. Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients—a case-control study. J Surg Oncol. 2014;110:661–5.

    Article  PubMed  Google Scholar 

  25. Sugarbaker P, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol. 1999;6:727–31.

    Article  CAS  PubMed  Google Scholar 

  26. Aletti GD, Santillan A, Eisenhauer EL, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol. 2007;107:99–106.

    Article  PubMed  Google Scholar 

  27. Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res. 1979;73:2264–8.

    Google Scholar 

  28. Alberts DS, Peng YM, Chen HS, et al. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Nat Cancer Inst. 1980;73:455–61.

    Google Scholar 

  29. Xu MJ, Alberts DS. Potentiation of platinum analogue cytotoxicity by hyperthermia. Cancer Chemother Pharmacol. 1988;21:191–6.

    Article  CAS  PubMed  Google Scholar 

  30. Maymon R, Bar-Shira Maymon B, Holzinger M, Tartakovsky B, & Leibovici J. Augmentative effects of intracellular chemotherapy penetration combined with hyperthermia in human ovarian cancer cells lines. Gynecol Oncol. 1994;55:265–70.

    Article  CAS  PubMed  Google Scholar 

  31. Istomin YP, Zhavrid EA, Alexandrova EN, Sergeyeva OP, & Petrovich SV. Dose enhancement effect of anticancer drugs associated with increased temperature in vitro. Exp Oncol. 2008;30:56–9.

    CAS  PubMed  Google Scholar 

  32. Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22:1570–5.

    Article  CAS  PubMed  Google Scholar 

  33. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107:588–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Harter P, Beutel B, Alesina PF, et al. Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecol Oncol. 2014;132:537–41.

    Article  PubMed  Google Scholar 

  36. Zang RY, Harter P, Chi DS, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011;105:890–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Fotopoulou C, Zang R, Gultekin M, et al. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation. Ann Surg Oncol. 2013;20:1348–54.

    Article  PubMed  Google Scholar 

  38. Kommoss S, Rochon J, Harter P, et al. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann Surg Oncol. 2010;17:279–86.

    Article  CAS  PubMed  Google Scholar 

  39. Morgan RJ Jr, Alvarez RD, Armstrong DK, et al; National Comprehensive Cancer Networks. Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 2013;11:1199–209.

  40. Harter P, Mahner S, Hilpert F, et al. Statement by the Kommission OVAR of the AGO Study Group on the use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to treat primary and recurrent ovarian cancer. Geburtshilfe Frauenheilkd. 2013;73:221–3.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Disclosure

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Gynecologic Oncology, AC Camargo Cancer Center, São Paulo, Brazil

    Glauco Baiocchi MD, PhD, Henrique Mantoan MD, Carlos Chaves Faloppa MD & Lillian Yuri Kumagai MD

  2. Department of Pelvic Surgery, AC Camargo Cancer Center, São Paulo, Brazil

    Fabio Oliveira Ferreira MD, PhD, Renata Mayumi Takahashi MD, Wilson Toshihiko Nakagawa MD, PhD, Samuel Aguiar Jr. MD, PhD & Ademar Lopes MD, PhD

  3. Department of Medical Oncology, AC Camargo Cancer Center, São Paulo, Brazil

    Alexandre Andre Balieiro Anastacio da Costa MD & Celso Abdon Lopes de Mello MD, PhD

Authors
  1. Glauco Baiocchi MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabio Oliveira Ferreira MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henrique Mantoan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexandre Andre Balieiro Anastacio da Costa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carlos Chaves Faloppa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lillian Yuri Kumagai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Celso Abdon Lopes de Mello MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Renata Mayumi Takahashi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wilson Toshihiko Nakagawa MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Samuel Aguiar Jr. MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ademar Lopes MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Glauco Baiocchi MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baiocchi, G., Ferreira, F.O., Mantoan, H. et al. Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis. Ann Surg Oncol 23, 1294–1301 (2016). https://doi.org/10.1245/s10434-015-4991-4

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-015-4991-4

Keywords

Search

Navigation